For the study, researchers used mouse models to examine bites from the Aedes aegypti mosquito — the primary culprit in the recent outbreak of Zika in the Western Hemisphere. When a mosquito bites, the insect injects saliva into the skin, which then incites a response from the immune system. White blood cells rush to the location of the bite, but instead of combating potential infections, some of the cells become infected and begin inadvertently replicating the virus, helping the infection to spread. When researchers infected mice with Zika sans mosquito bite, the virus failed to replicate as well.
Clive McKimmie, PhD, a research fellow at the University of Leeds in the United Kingdom and senior author of the study, said, “We now want to look at whether medications such as anti-inflammatory creams can stop the virus establishing an infection if used quickly enough after the bite inflammation appears.”
More articles on the Zika virus:
10,000 pregnant women to be enrolled in multinational Zika study
Hundreds of infants in Puerto Rico could be born with Zika-related birth defects, says CDC
Hologic’s diagnostic assay for Zika earns emergency use clearance from FDA
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
